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Abstract. Proteins in the TGF-[~ superfamily transduce 
their effects through binding to type I and type II 
serine/threonine kinase receptors. Osteogenic protein-1 
(OP-1, also known as bone morphogenetic protein-7 or 
BMP-7), a member of the TGF-[3 superfamily which 
belongs to the BMP subfamily, was found to bind ac- 
tivin receptor type I (ActR-I), and BMP receptors type 
IA (BMPR-IA) and type IB (BMPR-IB) in the pres- 
ence of activin receptors type II (ActR-II) and type liB 
(ActR-IIB). The binding affinity of OP-1 to ActR-II 
was two- to threefold lower than that of activin A. A 
transcriptional activation signal was transduced after 
binding of OP-1 to the complex of ActR-I and ActR-II, 
or that of BMPR-IB and ActR-II. These results indi- 
cate that ActR-II can act as a functional type II recep- 
tor for OP-1, as well as for activins. Some of the known 
biological effects of activin were observed for OP-1, in- 
cluding growth inhibition and erythroid differentiation 
induction. Compared to activin, OP-1 was shown to be 
a poor inducer of mesoderm in Xenopus embryos. 
Moreover, follistatin, an inhibitor of activins, was found 
to inhibit the effects of OP-1, if added at a 10-fold ex- 
cess. However, certain effects of activin, like induction 
of follicle stimulating hormone secretion in rat pituitary 
cells were not observed for OP-1. OP-1 has overlapping 
binding specificities with activins, and shares certain 
but not all of the functional effects of activins. Thus, 
OP-1 may have broader effects in vivo than hitherto 
recognized. 
B 
ONE  morphogenetic proteins  (BMPs) 1 were  origi- 
nally identified as proteins that induce bone and 
cartilage formation in ectopic extraskeletal sites in 
vivo  (reviewed in Reddi, 1992; 1994; Wozney, 1989). In 
vitro studies have revealed that BMPs have multiple ef- 
fects on many different cell types, e.g., stimulation of pro- 
teoglycan  synthesis  in  chondrocytes  (Vukicevic  et  al., 
1989), synthesis  of collagen and alkaline phosphatase in 
osteoblasts (Vukicevic et al., 1989), and differentiation of 
neural cells  (Paralkar et al.,  1992; Perides et al.,  1994). 
BMPs also play important roles in the embryonal develop- 
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ment, e.g., in ventral mesoderm induction (Dale  et  al., 
1992; Jones et al., 1992). Many proteins belong to the BMP 
family, including BMP-2 to -6, osteogenic protein-1  (OP-1, 
also termed BMP-7), OP-2 (BMP-8), and growth/differen- 
tiation factor-5 to -7 (Burt and Law, 1994; Kingsley, 1994; 
Massagu6  et al., 1994). Some  of the members are more 
closely related to each other than to the other members in 
the BMP family, and thus, BMPs can be divided into sub- 
groups. BMP-4 and OP-1 belong to different subgroups. 
Activins were originally identified as factors in ovarian 
fluid that  stimulate the  secretion of follicle  stimulating 
hormone (FSH) from pituitary cells (reviewed  in Vale et 
al., 1990); in contrast, inhibins  inhibit FSH secretion.  In- 
hibins are composed of heterodimers of one et chain and 
one 13 chain (13A or 13a  chains).  Activins  are dimers of 13 
chains; a homodimer of 13A chains is denoted activin A. Ac- 
tivins  are multifunctional proteins; they stimulate meso- 
derm induction in Xenopus embryos (Smith  et al.,  1990; 
van den Eijnden-Van Raaij et al., 1990; Asashima et al., 
1990; Thomsen et al., 1990), stimulate the differentiation 
of erythroid progenitor cells (Murata et al., 1988; Huyle- 
broeck et al., 1990), and modulate the bone formation by 
BMP (Ogawa et al., 1992). 
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termed the TGF-13 superfamily, which contains TGF-13s, 
Mtillerian inhibiting substance, and glial cell line-derived 
neurotrophic  factor  (reviewed  in  Burt  and  Law,  1994; 
Kingsley, 1994; Massagu6 et al.,  1994).  Significant amino 
acid  sequence  similarities  were  observed  between  the 
members in the TGF-[3 superfamily. Moreover, seven cys- 
teine residues are conserved in most of the members in the 
TGF-I~  superfamily,  suggesting  that  they  have  similar 
three-dimensional structures. 
The members of the TGF-13 superfamily exert their ef- 
fects through binding to two types of specific receptors, 
termed type I  (molecular mass of ~53  kD)  and type II 
(~70  kD)  receptors  (Massagu6  et  al.,  1994; Mathews, 
1994; ten Dijke et aL,  1994a).  Types I  and II receptors 
form heteromeric receptor complexes after ligand binding 
and are indispensable for signal transduction (Wrana et 
al.,  1992, 1994; Inagaki et al.,  1993; Attisano et al., 1993; 
Franz6n et al., 1993). Two different forms of activin type II 
receptors, ActR-II and ActR-IIB, have been cloned and 
shown  to  have  intracellular serine/threonine kinase  do- 
mains  (Mathews  and  Vale,  1991; Attisano  et  al.,  1992; 
Mathews et al., 1992). The TGF-I3 type II receptor (TI3R- 
II) is also a transmembrane serine/threonine kinase (Lin 
et al., 1992). DAF-4 from Caenorhabditis  elegans serves as 
a type II receptor for BMP-2, BMP-4, and OP-1, although 
signaling activity after binding of BMPs has not been dem- 
onstrated (Estevez et al., 1993; ten Dijke et al., 1994b). 
A series of serine/threonine kinase receptors have been 
cloned and denoted activin receptor-like kinase (ALK)-I 
through ALK-6 by us (Franz6n et al., 1993; ten Dijke et 
al., 1993, 1994c). ALKs have been shown to serve as type I 
receptors for members of TGF-13 superfamily (Table  I). 
ALK-5 is a TGF-~ type I receptor (TIeR-I) (Franz6n et al., 
1993; Bassing et  al.,  1994; ten  Dijke  et  al.,  1994c),  and 
ALK-2 and ALK-4 are activin type I  receptors  (ActR-I 
and ActR-IB, respectively) (Ebner et al., 1993a; Attisano 
et al.,  1993; Tsuchida et al.,  1993; ten Dijke et al.,  1994c; 
C~ircamo et al., 1994). In addition, ALK-3 and -6 have re- 
cently been shown to be type I receptors for the proteins 
in  the  BMP  family (BMPR-IA  and  BMPR-IB,  respec- 
tively) (ten Dijke et al., 1994b; Koenig et al., 1994; Graft 
et al.,  1994; Suzuki et al., 1994). BMPR-IA and -IB bind 
Table L Mammalian Serine/Threonine Kinase Receptors for the 
OP-1 and BMP-4 in the presence of DAF-4, although the 
binding of OP-1 to BMPR-IA is weaker than that of BMP-4. 
Furthermore, ActR-I can bind OP-1 but not BMP-4 in the 
presence of DAF-4 (ten Dijke et al., 1994b). 
A certain redundancy in the ligand binding of the type I 
receptors has been reported (Ebner et al., 1993a; Attisano 
et  al.,  1993; ten Dijke et  al.,  1994c). In contrast, ligand 
binding to  the  type II receptors  has  been  shown to  be 
highly specific, i.e., TI3R-II binds only TGF-I3s,  ActR-II, 
and ActR-IIB bind only activin and inhibin, and DAF-4 
binds only BMPs (Mathews and Vale 1991; Attisano et al., 
1992; Mathews et al., 1992; Lin et al., 1992; Estevez et al., 
1993) (Table I). However, since ActR-I acts as a type I re- 
ceptor for activins in the presence of ActR-II or ActR-IIB 
(Attisano et al., 1993; Ebner et al., 1993a; Tsuchida et al., 
1993; ten Dijke et al.,  1994c), and also binds OP-1 in the 
presence of DAF-4 (ten Dijke et al., 1994b),  we investi- 
gated in the present work whether OP-1 can bind to ActR- 
IIs and transduce activin-like signals. 
Materials and Methods 
Cell Culture 
Mink lung epithelial ceils (MvlLu) and COS-1 cells were obtained from 
American  Type  Culture  Collection  (Rockville,  MD).  Chemically mu- 
tagenized MvlLu cell line (R mutant, clone 4-2) (Laiho et al., 1990) was a 
gift from M. Laiho (University of Helsinki, Helsinki, Finland) and J. Mas- 
sagu6 (Memorial Sloan-Kettering Cancer Center, New York). The cells 
were cultured in DME containing 10% fetal bovine serum and antibiotics 
(100 U/ml penicillin and 50 jxg/ml streptomycin) in 5% CO2 atmosphere at 
37°C. A  human erythroleukemia cell line, K562 (American Type Culture 
Collection),  was  cultured  in  RPMI-1640  buffered  with  25  mM Hepes 
buffer containing 10%  fetal bovine serum and antibiotics. Rat pituitary 
cells were obtained from 14-d-old female Wistar rats. The rats were de- 
capitated and pituitaries were cut into small tissue blocks and enzymati- 
cally dispersed as described previously (Denef et  al.,  1989).  For  FSH- 
release experiments, cells were seeded in 24-well tissue plates at a density 
of 2 x  10  ~ cells/100 iJ,  l/well. After an adhesion period of about 30 rain, 1 ml 
of serum-free culture medium was added per well. The serum-free me- 
dium consisted of DME and Ham's F-12 (1:1  of vol/vol), 15 mM Hepes 
buffer, 20 ~xM ethanolamine and 20 nM sodium selenite (special powder 
mixture prepared by Gibco Europe, Paisley, UK) to which were added 5 
mg/ml  bovine  serum  albumin  prepared  from  a  30%  stock  solution 
(Gibco),  1 mg/ml NaHCO3, 8 p.g/ml transferrin (Gibco), 5 ~g/mi insulin 
(Boehringer Mannheim Biochemicals, Indianapolis, IN), 1 p.g/ml catalase 
(Serva, Heidelberg, Germany), 10 nM ethanol, 35 p.g/ml penicillin, 50 p,g/ml 
TGF-fl Superfamily 
Designation  Ligands  Other designations 
Type II receptors 
ActR-II  activins, OP-I* 
ActR-IIB  activins, OP- 1' 
TI3R-II  TGF-I3s 
Type I receptors 
ActR-I  activins, *OP-1 
ActR-IB  activins 
TI3R-I  TGF-13s 
ALK-1  unknown 
BMPR-IA  OP- 1.§ BMP-4, BMP-2 
BMPR-IB  OP- 1, BMP-4 
ALK-2 (ten Dijke et al., 1993), SKR-1 (Matsuzaki et al., 1993), Tsk-7L (Ebner et al., 1993b), 
R1 (He et al., 1993) 
ALK-4 (ten Dijke et al., 1993), SKR-2 (Xu et al., 1994), R2 (He et al., 1993) 
ALK-5 (Franz6n et al., 1993), R4 (He et al., 1993) 
TSR-1 (Attisano et al., 1993), R3 (He et al., 1993) 
ALK-3 (ten Dijke et al., 1993), BRK-1 (Koenig et al., 1994) 
ALK-6 (ten Dijke et al., 1994c) 
*Binding  has been shown in the present report. 
*Redundancy  in the binding of TGF-[3 and activin to type I receptors have been observed; TGF-13  and acnvin are hsted m this table only if they are known to transduce signals (At- 
ttsano et al., 1993; Franz6n et al, 1993; Bussing et al., 1994; ten Dijke et al., 1994c; Ciircamo et al., 1994). 
~The binding of OP-1 to BMPR-IA is weaker than that of BMP-4 (ten Dijke et al., 1994/7). 
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0.05  nM  triiodothyronine.  For  cross-linking  experiments,  cells  were 
seeded in six-well plates in a density of 3.33  ×  106 cells/ml/well. They were 
allowed to adhere for about 30 min, and then 2 ml of DME supplemented 
with 10% fetal bovine serum, I mg/ml NaHCO3 and antibiotics was added 
to each well. Pituitary cells were cultured in a humidified CO  2 (1.5%) air 
incubator at 37°C. 
Recombinant Proteins 
Recombinant human BMP-4, recombinant human TGF-131 and recombi- 
nant human activin A  were obtained from A. H. Reddi (Johns Hopkins 
University,  Baltimore,  MD),  H.  Ohashi  (Kirin  Brewery  Company, 
Maebashi, Japan) and Y. Eto (Ajinomoto Company, Inc., Kawasaki, Ja- 
pan), respectively. Recombinant bovine activin A  used in mesoderm in- 
ducing assays was obtained from Innogenetics. Recombinant human fol- 
listatin (B4384) was obtained from the National Hormone and Pituitary 
Program (Rockville, MD). 
Recombinant human OP-1 was obtained as described (Ozkaynak et al., 
1990; Sampath et aL, 1992),  In order to confirm that recombinant human 
OP-1 does not contain activin-like molecules, OP-1 was radiolabeled with 
125I (see below) and analyzed by SDS-gel electrophoresis. 125I-OP-1 was 
observed as multiple components with molecular masses of 30-38 kD un- 
der nonreducing condition and 16-19 kD  under reducing condition. In 
contrast, 125I-activin A was observed as a 25-kD component under nonre- 
ducing condition and a 13-kD component under reducing condition. Anal- 
ysis of OP-1 by reverse phase high performance liquid chromatography 
revealed  three  major  components eluting  very  closely  to  each  other. 
Amino acid sequencing of these components revealed sequences only of 
mature OP-1; no activin sequences were found. 
Recombinant human soluble OP-1, which is a complex containing the 
NHE-terminal  pro-domain  and  the  mature  OP-1,  was  obtained  as  de- 
scribed (Jones et al., 1994). 
Transient Transfection of cDNAs 
cDNAs for type I receptors were cloned as described (Franz6n et al., 1993; 
ten  Dijke  et  al.,  1993,  1994c).  ActR-II  eDNA  was  a  gift  from  L.  S. 
Mathews and W. W. Vale  (Salk  Institute, San Diego,  CA).  ActR-IIB1 
eDNA and p3TP-Lux promoter-reporter construct were obtained from J. 
Massagu6, J. L. Wrana and L. Attisano (Memorial Sloan-Kettering Can- 
cer Center). For transient transfection, cDNAs for type I or type II recep- 
tors subcloned into pSV7d (Truett et al,, 1985), pcDNA I (Invitrogen, San 
Diego, CA) or pCMV5 (Andersson et al,,  1989)  expression vectors were 
used. These plasmids and p3TP-Lux promoter-reporter construct (5  }xg 
for each) were transfected into COS-1 or R  mutant MvlLu cells by a cal- 
cium phosphate precipitation method with a mammalian transfection kit 
(Stratagene Corp., La Jolla, CA), following the manufacturer's protocol. 
In brief, cells were seeded into 6-well cell culture plates at a  density of 
5 ×  105 cells/well and transfected with 5 p,g of plasmids on the following 
day. After overnight incubation, cells were washed four times with phos- 
phate-buffered saline  (pH 7.4)  and then incubated in DME  containing 
10% fetal bovine serum and antibiotics. One or two days after, the cells 
were used for cross-linking and immunoprecipitation studies or transcrip- 
tional response assay. 
Preparation of Polyclonal  Antibodies 
Antisera against type I  receptors were made against synthetic peptides 
corresponding to the intracellular juxtamembrane parts of type I recep- 
tors as previously reported (Franzrn et at., 1993; ten Dijke et at., 1994c). 
Antiserum against ActR-II  (ARC-2), which detects  only ActR-II,  was 
generated against a peptide corresponding to the COOH-terminal tail of 
ActR-II (Ichijo et al., 1993).  Antiserum against the intracellular part of 
ActR-II,  which  cross-reacts with  ActR-IIB,  was  a  gift  from  K.  Vers- 
chueren (University of Leuven, Leuven, Belgium). 
Radiolabeling of Ligands, Binding, Affinity 
Cross-linking, and Immunoprecipitation 
Activin A was iodinated using the chloramine T method according to Fro- 
lik et al. (1984). OP-1 and BMP-4 were iodinated by the same method, but 
chloramine T was added two times. Ceils were incubated on ice for 2-3 h 
with 0.2-0.5 nM of 125I-labeled ligands in the presence or absence of unla- 
beled ligands in the binding buffer (phosphate-buffered saline containing 
0.9 mM CaCI2, 0.49 mM MgCI2 and I mg/ml bovine serum albumin). After 
incubation, the cells were washed with the binding buffer without bovine 
serum albumin and cross-linking was done in the same buffer containing 
0.28 mM of disuccinimidyl suberate (DSS) or 1 mM bis(sulfosuccinimidyl) 
suberate (BS  3) (Pierce Chemical Co., Rockford, IL) for 15 rain on ice. The 
cells were washed once with 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10% 
glycerol  and  0.3  mM  phenylmethylsulphonyl fluoride.  The  cells  were 
scraped in the same buffer, centrifuged and resuspended in solubilization 
buffer (150 mM NaCI, 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0,3 mM 
phenylmethylsulphonyl  fluoride, 1.5 % Trasylol, 1% Triton X-100, and 1% 
deoxycholate), followed by incubation for 20 min on ice. Cross-linked ma- 
terials were then incubated with antisera for 1 h  at 4°C. Thereafter, 50/~1 
of a protein A-Sepharose (Immunosorb A; EC Diagnostics AB Uppsala, 
Sweden) slurry (50% packed beads in solubilization buffer) was added to 
immune complexes and the mixture was incubated for 1 h  at 4°C. The 
beads were spun down and washed two times with 20 mM Tris-HC1, pH 
7.4,  500 mM NaC1,  1% Triton X-100, 1% deoxycholate, and 0.2% SDS, 
followed by one time wash in distilled water. The immune complexes were 
eluted by boiling 3 rain in the SDS sample buffer with 10 mM dithiothrei- 
tol, and subjected to SDS-gel electrophoresis, followed by autoradiogra- 
phy using Hyperfilm (Amersham Corp., Arlington Heights, IL) or analy- 
sis by a Phosphorlmager (Molecular Dynamics, Eugene, OR). 
[3H]Thymidine Incorporation Assay 
MvlLu cells were seeded in 24-well plates at a density of 104 cells per well 
in DME with 5% fetal bovine serum and antibiotics (100 U/ml penicillin 
and 50  Ixg/ml streptomycin). After 24 h, the medium was changed into 
DME with 1% fetal bovine serum and antibiotics containing various con- 
centrations of TGF-131, OP-1 or activin A  in the presence or absence of 
follistatin. After 16-18 h  of incubation, 0.3 p,  Ci of [3H]thymidine (85 Ci/ 
retool; Amersham Corp.) was added and the cells were incubated for an 
additional 2 h. Thereafter, the cells were fixed in 5% ice-cold trichloroace- 
tic acid for more than I  h, and soinbilized with I M NaOH for more than 
20 rain. The cell extract was neutralized with 1 M HC1 and 3H-radioactiv- 
ity was determined in a liquid scintillation counter using Ecoscint A  (Na- 
tional Diagnostics, Atlanta, GA). 
Plasminogen Activator Inhibitor-1 (PAI-1)  Assay 
PAI-1  induction  by TGF-131,  OP-1,  and  activin  A  was investigated in 
MvlLu cells and R mutant MvlLu cells according to the method reported 
previously (Laiho et al., 1991:  Franzrn et at., 1993).  In brief, cells were 
seeded in  6-well cell culture  plates  and incubated overnight. The cells 
were exposed to TGF-I~I, OP-1, or activin A  in serum-free MCDB 104 
medium without methionine for 2  h, Thereafter, cultures were  labeled 
with  [3SS]methionine (40 mCi/ml) for 2  h. The  cells were  removed by 
washing on ice once in phosphate-buffered saline, three times in 10 mM 
Tris-HCl, pH 8.0, 0.5% sodium deoxycholate, and 1 mM phenylmethylsul- 
phonyl fluoride, two times in 2 raM Tris-HCl, pH 8.0, and once in phos- 
phate-buffered saline. Extracellular-matrix proteins were scraped off and 
extracted into SDS sample buffer containing dithiothreitol and analyzed 
by  SDS-gel  electrophoresis,  followed  by  fluorography  using Amplify 
(Amersham Corp.). PAI-1 was identified as a 45-kD protein (Laiho et at., 
1991). 
Transcriptional Response  Assay 
R  mutant MvlLu  cells were  co-transfected with  p3TP-Lux promoter- 
reporter construct (Wrana et al., 1992; Attisano et al., 1993) with plasmids 
containing type I  or type II receptor cDNAs as described above.  Cells 
were  washed with phosphate-buffered saline on the following day. The 
cells were starved in DME containing 0.1% of fetal bovine serum and an- 
tibiotics (100 U/ml penicillin and 50 }~g/ml streptomycin) for 6 h and then 
exposed to TGF-IM, OP-1, or activin A  for 24 h. Luciferase activity in the 
cell lysate was measured using the luciferase assay system (Promega Bio- 
tec, Madison, WI) according to the manufacturer's protocol, using a lumi- 
nometer (model 1250; LKB Instruments, Inc., Bromma, Sweden). 
Erythroid Differentiation ofK562 Cells 
Erythroid differentiation was tested using K562 cells. Activin A and OP-1 
were subjected to twofold serial dilution in RPMI-1640 medium buffered 
with 25 mM Hepes buffer and supplemented with 10% fetal bovine serum. 
Dilution was performed in 96-well plates with final volumes of 100 }xl. 
1-2 ×  104 cells in 100 p,l were added to each well of 96-well plate, and cells 
were incubated for 4--7 d  at 37°C.  Thereafter, the cells were stained by 
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agent consists of 4 mg/ml benzidine dihydrochloride in 0.5% acetic acid to 
which hydrogen peroxide is added just before use. The reagent and cell 
suspension were mixed in a microtiter plate. The cells with hemoglobin 
were stained blue; in contrast, the cells without hemoglobin were stained 
yellow. The proportion of hemoglobin positive cells was determined by 
counting. 
For the induction of hemoglobin synthesis, K562 cells in DME contain- 
ing serum (105 cells/ml) were treated with activin A  or OP-1 and incu- 
bated for five days before harvesting. Heroin was used as a positive con- 
trol (Huylebroeck et al., 1990). The hemoglobin content in K562 cells was 
measured by optical absorption, as described (Okabe  et al.,  1984). The 
cells were chilled on ice, washed two times with ice-cold phosphate-buff- 
ered saline, and cell pellets were resuspended in lysis buffer containing 
140 mM NaCI, 2 mM magnesium acetate, and 10 mM Tris-HCl, pH 7.4, 
and 0.5% NP-40. After 15 min on ice, the nuclei were removed by centri- 
fugation and the absorption was measured at 414 nm. The hemoglobin 
content was normalized to the cell number and the increase compared to 
the control was calculated. 
FSH Release  from Rat lh'tuitary Cells 
The rat pituitary cells were prepared as described above; on the second 
day the serum-free medium was removed and I  ml of fresh serum-free 
medium with test substances was added. After incubation for an  addi- 
tional two days, the medium was collected and FSH concentration was de- 
termined by radioimmunoassay (RIA). Each test substance was added to 
four wells and RIA was performed in duplicate using the FSH-RIA kit 
(National Institute of Diabetes and Digestive and Kidney Diseases, Rock- 
ville, MD) according to the methods of Denef et al. (1989). 
Xenopus Embryo Culture, Dissections, and Mesoderm 
Induction Assays 
Xenopus laevis embryos were obtained by artificial fertilization as de- 
scribed by Smith and Slack (1983). They were dejellied with cysteine hy- 
drochloride  (pH  8.1)  and  staged  according to  Nieuwkoop  and  Faber 
(1967).  Animal caps were dissected from embryos at  stage 8  with fine 
watchmaker's forceps and they were cultured in 75% normal amphibian 
medium (NAM; Slack, 1984) containing 0.1% bovine serum albumin and, 
where appropriate, bovine activin A (Innogenetics, Gent, Belgium) or sol- 
uble OP-1. Some experiments used crude human activin A. For this mate- 
rial, one inducing U/ml (~8 pM; Cooke et al., 1987) is defined as the mini- 
mum concentration necessary for mesoderm induction to occur. 
RNAase Protections 
RNA  was isolated and  hybridized with radioactive probes specific for 
Xenopus Brachyury (Xbra) and EF-la essentially as described by Cuniiffe 
and Smith (1994). 
Results 
Binding of OP-1 to ActR-IIs and Type I Receptors 
Expressed in COS Cells 
To investigate whether ActR-II can serve as a type II re- 
ceptor for OP-1, cDNAs for ActR-II, and different type I 
receptors were co-transfected into COS-1 cells. The cells 
were then incubated with 125I-OP-1,  followed by cross- 
linking with DSS. Since the cross-linked complexes were 
difficult to  analyze directly by SDS-gel electrophoresis 
because  of  high  background,  cross-linked  complexes 
were immunoprecipitated using antisera against ActR-II 
or type I receptors. When only ActR-II eDNA was trans- 
fected, 125I-OP-1 bound to ActR-II, as determined by the 
immunoprecipitation  of  a  cross-linked  complex of  the 
expected  size  using  the  ActR-II  antiserum  (Fig. 1  A). 
ActR-I,  BMPR-IA,  and  BMPR-IB  bound  125I-OP-1  in 
the presence of ActR-II, but the other type I  receptors 
did not. Co-immunoprecipitation of ActR-II with ActR-I, 
BMPR-IA, or BMPR-IB could be observed in the pres- 
ence of t25I-OP-1  using antisera against ActR-II or type I 
receptors (Fig. 1 A). In most experiments, binding of 125I- 
OP-1  to BMPR-IA  was weaker than that to ActR-I or 
BMPR-IB. Binding of 125I-OP-1 to ActR-IIB~, one of the 
spliced forms of the second activin type II receptor (Atti- 
sano et al., 1992), was also investigated. ActR-IIBx alone 
bound  125I-OP-1 weakly, but it bound  efficiently in  the 
presence of ActR-I, BMPR-IA, or BMPR-IB (Fig. 1 B). 
ActR-IIB1 complexes were co-immunoprecipitated with 
antisera against type I receptors and vice versa. 
For comparison, the binding of ~25I-BMP-4 to ActR-IIs 
Figure 1.  Binding of OP-1 to ActR-IIs and type I  receptors. COS-1 cells were transfected with cDNAs for ActR-II (,4) or ActR-IIBl 
(B) together with those for type I receptors. The cells were affinity labeled using ~25I-OP-1, followed by cross-linking with DSS. Cell ly- 
sates were immunoprecipitated with antisera against ActR-II (ARC-2) (A), type I  receptors (A and B), or the ActR-II antiserum that 
cross-reacts with ActR-IIB (B). Samples were analyzed by SDS-gel electrophoresis followed by autoradiography (A) or analysis using a 
Phosphorlmager (B). Markers of molecular mass are indicated to the left. A1, ALK-1; A2, ActR-I/ALK-2; A3, BMPR-IA/ALK-3; A4, 
ActR-IB/ALK-4; A5, TI3R-I/ALK-5; A6, BMPR-IB/ALK-6, II, ActR-II; liB, ActR-IIB. 
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ActR-IIs, using  the  antisera  to  ActR-II and  ActR-IIB  1. 
125I-BMP-4  did  not  bind  to  ActR-II  or  ActR-IIB  1 effi- 
ciently, consistent with the previous report (Attisano et al., 
1992). 
Binding of OP-1 to ActR-H on MvlLu Cells 
When type I receptors were overexpressed in COS-1 cells 
together with T[3R-II or ActR-II, almost all type I recep- 
tors formed complexes with TGF-[3 or activin, respectively 
(Ebner et al., 1993a; Attisano et al., 1993; ten Dijke et al., 
1994c). These results indicate that ligand binding to recep- 
tors expressed at very large numbers in COS-1 cells may 
not indicate a physiologically significant interaction. There- 
fore,  we  have  tested  the  binding  of  OP-1  to  nontrans- 
fected,  responsive  cells  with  normal  receptor  numbers. 
Wild type MvlLu cells express ActR-II, ActR-I, ActR-IB 
(ten Dijke et al., 1994c), and respond to activin A  with re- 
gard to growth inhibition  and PAI-1 production (see be- 
low).  When  the  MvlLu cells were  affinity labeled using 
Figure 2. Binding  of 125I-OP-1 and l~I-activin A  to ActR-II on 
MvlLu cells and competition by unlabeled ligands. MvlLu cells 
were affinity labeled using 125I-OP-1 or 125I-activin  A (Act A), fol- 
lowed by cross-linking by DSS. The cross-linked complexes were 
immunoprecipitated with  the ActR-II antiserum (ARC-2). (A) 
Binding  of l~I-OP-1 (0.3 nM) or 125I-activin A  (0.4 riM) in the 
presence or absence of unlabeled OP-1 (17 nM) or activin A (20 
nM). (B and C) Binding of I~I-OP-1 (0.5 nM) (B) and125I-activin 
A  (0.2 riM) (C) in the presence of different concentrations of 
unlabeled  activin  A  or  OP-1. The  competition  of binding  of 
125I-labeled ligands by unlabeled OP-1  or activin A was quanti- 
tated by the amounts of radioactivity  in the ActR-II complex us- 
ing  a  Phosphorlmager. Experiments have been repeated using 
different concentrations of unlabeled ligands, and representative 
data are shown. 
125I-OP-1  and  cross-linked,  a  90-kD  ActR-II  complex 
could be immunoprecipitated with the antiserum specific 
for ActR-II (Fig. 2 A). The binding of 125I-OP-1 to ActR- 
II was decreased to 30% in the presence of more than 50- 
fold excess of unlabeled OP-1 or activin A. Similarly, the 
binding  of 125I-activin  A  to  ActR-II in  MvlLu cells was 
competed with unlabeled  activin A, and also with OP-1, 
although less efficiently (Fig. 2 A). 
To compare the binding affinity of OP-1 and activin A 
to ActR-II, the  binding  of 125I-labeled  ligands  was com- 
peted with different concentrations  of unlabeled ligands. 
The  amounts  of  radioactivity  in  the  cross-linked  com- 
plexes containing ActR-II were quantitated using a Phos- 
phorlmager. Half maximal competition of 125I-OP-1  (0.5 
nM) binding to ActR-II in MvlLu cells occurred at about 
1.8 nM unlabeled activin A  and 5 nM unlabeled OP-1 (Fig. 
2 B). Half maximal competition of 125I-activin A  (0.2 nM) 
binding  to ActR-II in  these  cells also  occurred  at about 
2 nM activin and 5 nM OP-1 (Fig. 2 C). Taken together, ac- 
tivin A  appears to have two- to threefold higher affinity 
than OP-1 for binding to ActR-II on MvlLu cells. 
Growth Inhibitory Activity of OP-1; Neutralization 
by Follistatin 
Growth  inhibitory  activity  of  OP-1  was  compared  with 
those of TGF-IM and activin A. [3H]Thymidine incorpora- 
tion into MvlLu cells was found to be inhibited by OP-1, 
but both activin A  and OP-1 were about 100-fold less po- 
tent than TGF-[~I (Fig. 3 A). Follistatin is a  protein that 
specifically binds activins and neutralizes their biological 
activities (Ueno et al., 1987; Nakamura et al., 1990). There- 
fore, as expected, the growth inhibition by activin A  was 
abolished by the  addition  of equal  amount of follistatin. 
The effect of OP-1 was also neutralized by follistatin; how- 
ever, the neutralization was observed when follistatin was 
added at concentrations of more than 10 times of that of 
OP-1  (Fig. 3 B). Follistatin did not neutralize the growth 
inhibitory activity of TGF-[31 even when added at a 3,000- 
fold excess. 
Signal Transduction of OP-1 through ActR-H 
TGF-[31  stimulates  the  production  of  PAI-1  protein  in 
A  B  ~4o 
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Figure 3.  Growth inhibitory effects of OP-1 on MvlLu ceils, and 
neutralization  by follistatin.  (A) Effects of TGF-B1  (11), OP-1 
(e),  and  activin  A  (A)  on  [3H]thymidine  incorporation  into 
MvlLu ceils. (B) Effects of follistatin on the inhibitory  effects of 
activin A (10 nM; A) and OP-1 (10 nM; O) on [3H]thymidine in- 
corporation into MvlLu ceils. Open inverted triangles  (V) show 
the effect of follistatin  on [3H]thymidine incorporation without 
any growth factors. 
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ter the stimulation  by TGF- 
131, OP-1,  and  activin  A  in 
MvlLu  ceils. MvlLu  cells 
were  incubated  with  TGF- 
131 (0.8 nM),  OP-1 (7.3 nM), 
or activin A (4 nM) for 2 h. Then the cells were metabolically la- 
beled with  [35S]methionine for an additional  2 h. Extracellular 
matrix proteins were recovered, and the production of the 45-kD 
PAI-1  protein  was  analyzed  by  SDS-gel  electrophoresis,  fol- 
lowed by fluorography. 
MvlLu cells (Laiho et al., 1991).  Similarly, OP-1  and ac- 
tivin A  induced the production of PAI-1 in the same cells, 
although the increase in the PAI-1 protein was less than 
that  induced  by TGF-[M  (Fig.  4).  In  R  mutant  MvlLu 
cells, which lack functional T[3R-I, TGF-[31 did not induce 
PAI-1 production (Franz6n et al., 1993); in contrast, OP-1 
and activin A  induced PAI-1 synthesis in these cells (data 
not shown). Thus, PAI-1 induction by OP-1 and activin A 
was not mediated through T[3R-I, but through specific re- 
ceptor(s) for OP-1 and activin A. 
We next investigated whether ActR-II transduces a sig- 
nal for OP-1. Instead of measuring the production of PAI-1 
protein,  we  used  the  TGF-~-responsive  luciferase  re- 
porter construct, p3TP-Lux, which contains a region of the 
human  PAI-1  gene  promoter  and  three  sets  of  tetra- 
decanoyl phorbol acetate-responsive elements. The p3TP- 
Lux  construct  is  more  suitable  for  quantitative  analysis 
(Wrana et al.,  1992;  Attisano et al.,  1993);  moreover, al- 
though the R  mutant cells express endogenous activin re- 
ceptors (ten Dijke et al., 1994c), significant transcriptional 
activation by  activin  can  be  detected  only after  the  co- 
transfection of cDNAs for ActR-IIs and ActR-I in this as- 
say system (Attisano et al.,  1993).  We co-transfected dif- 
ferent combinations of type II and  type  I  receptors and 
p3TP-Lux into the R  mutant cells, and tested the ligand- 
induced  transcriptional  activation.  When  R  mutant  cells 
were  transfected  only  with  the  p3TP-Lux  plasmid,  the 
transcription was not activated by the addition of TGF-[31 
(Okadome et al., 1994; Attisano et al., 1993; Bassing et al., 
1994). Transcriptional activation was not observed even by 
the  addition  of activin A  or  OP-1  (Fig.  5  A).  After co- 
transfection of p3TP-Lux and TI3R-I, TGF-[31 stimulated 
the  reporter  luciferase  transcription  (Okadome  et  al., 
1994;  Bassing  et  al.,  1994).  Transfection  of  ActR-I  or 
ActR-II with p3TP-Lux did not mediate induction  of lu- 
ciferase activity either  by activin A  or  OP-1  (Fig.  5 A). 
When  p3TP-Lux  was  co-transfected  with  ActR-I  and 
ActR-II into R  mutant cells, transcriptional activation was 
observed after stimulation by activin A  or OP-1 (Fig. 5 A). 
Similarly, BMPR-IB alone did not mediate the p3TP-Lux 
signal  after  stimulation  by  OP-1,  but  co-transfection  of 
BMPR-IB  and  ActR-II mediated  transcriptional  activa- 
tion in response to OP-1  (Fig.  5 A). However, activin A 
did not transduce the p3TP-Lux signal in the presence of 
BMPR-IB and ActR-II (data not shown).  The transcrip- 
tional  response  to  OP-1  occurred  in  a  dose-dependent 
manner (Fig. 5 B).  In R  mutant cells co-transfected with 
ActR-I and ActR-IIB1, the  activation of transcription by 
OP-1 was not detected after the stimulation by OP-1 at the 
concentration of 8.8 nM, and about twofold increase over 
baseline was detected at the concentration of 29 nM. 
Figure  5. Transcriptional  activation  by  OP-1  and  activin  A 
through ActR-II and type I receptors (ActR-I and BMPR-IB). 
Transcriptional  activation was measured using MvlLu R mutant 
cells transfected with p3TP-Lux promoter-reporter construct. (A) 
cDNAs for ActR-II, ActR-I and/or  BMPR-IB were  co-trans- 
fected with p3TP-Lux into the cells, and cells were stimulated  by 
OP-1  (8.8 riM) or activin A  (12 nM) for 24 h. (B) ActR-II and 
ActR-I cDNAs  were  co-transfected into  cells, and  cells  were 
stimulated  by different concentrations  of OP-1. Luciferase  activ- 
ity is expressed relative to a control without stimulation. The ex- 
periments were repeated two to five times with the same results 
each time. 
Erythroid Differentiation by Activin A and OP-1 
Activin  A  has  been  shown  to  induce  differentiation  of 
erythroid progenitor cells, K562 (Huylebroeck et al., 1990). 
The effects of OP-1 on K562 cells were studied. Activin A 
significantly induced  differentiation of K562 cells at con- 
centrations over 0.26 nM, whereas OP-1 induced the dif- 
ferentiation at concentrations over 6.7 nM (Fig. 6 A). Both 
activin  A  and  OP-1  also  induced  hemoglobin synthesis; 
also  in  this  case  activin  A  was  more  potent  than  OP-1 
(Fig. 6 B). 
In  order  to  identify  the  receptors  which  mediate  the 
erythroid  differentiation  of  these  cells,  binding  studies 
using  125I-labeled  ligands  were  performed. 125I-activin  A 
bound to type I and type II receptors for activins, and im- 
munoprecipitation of the cross-linked receptor-ligand com- 
plexes  by  antisera  revealed  that  ActR-I,  ActR-IB,  and 
ActR-II were expressed on K562 cells (Fig. 6 C). 125I-OP-1 
bound  to  ActR-I  and  ActR-II,  but  not  to  ActR-IB  or 
other type I receptors. These results suggest that erythroid 
differentiation by activin A  and OP-1 of K562 cells is. at 
least in part, induced through ActR-II and ActR-I. Since 
the erythroid differentiation in K562 cells was more signif- 
icant by activin A  than by OP-1, ActR-IB may also be in- 
volved in the stimulation pathway. 
FSH-release from Pituitary Cells by Activin A and OP-1 
Activin A is known to stimulate the secretion of FSH from 
pituitary ceils (Vale et al., 1990). In agreement with previ- 
ous  findings,  a  dose-dependent  increase  of FSH  release 
from rat pituitary cells was observed after the addition of 
activin A  (Fig. 7 A). In contrast, OP-1 did not stimulate the 
secretion of FSH even at a concentration of 6.7 nM. More- 
over, OP-1 did not antagonize the FSH release activity of 
activin A  (Fig. 7 B). 
To characterize the  receptors involved, the  binding  of 
xesI-labeled ligands to rat pituitary cells was investigated. 
leSI-activin A  bound rat pituitary cells and formed type II 
and  type  I  receptor  complexes. The  complexes between 
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OP-1 and identification of their  receptors. (A) K562 cells were 
seeded into 96-well plates and exposed to various concentrations 
of activin A (&) or OP-1 (O) for 4-7 d at 37°C before staining by 
benzidine. The proportion of hemoglobin positive cells was calcu- 
lated. (B) Hemoglobin synthesis in K562 cells induced by activin 
A (&) or OP-1 (O) was examined by the optical measurement 
of hemoglobin content. K562 cells were exposed to activin A or 
OP-1 for five days. Hemoglobin content was measured by the op- 
tical absorption at 414 nm and expressed relative to that of an un- 
stimulated control. (C) Binding of activin and OP-1 to the type I 
and type II receptors  on K562 cells. K562 cells were affinity la- 
beled using 12SI-activin  A (Act  A) or 125I-OP-1, followed by cross- 
linking by DSS. The cross-linked complexes were immunoprecip- 
itated  with the  ActR-II antiserum  (ARC-2), or with  antisera 
against type I receptors. Samples were subjected to SDS-gel elec- 
trophoresis, followed by autoradiography. 
Figure 7. FSH release from pituitary cells by activin A and OP-1 
and  identification  of activin receptors.  (A)  Rat  pituitary  cells 
were seeded in 24-well plates and the medium was changed into 
fresh medium containing activin A  (A) or OP-1 (O). The cells 
were incubated for another two days and FSH released into the 
medium was measured by RIA. The amount is expressed relative 
to an unstimulated control. (B) The possibility that OP-1 antago- 
nizes the FSH release by activin A was investigated. Rat pituitary 
cells were  exposed  to different  concentrations  of OP-1 in  the 
presence (11) or absence (O) of activin A (0. 4 nM), and FSH re- 
leased into the medium was determined as described above. (C) 
Rat pituitary cells were affinity labeled using 1251-activin A (Act 
A)  or  125I-OP-1, followed by cross-linking by BS 3. The  cross- 
linked  complexes  were  immunoprecipitated  with the  ActR-II 
antiserum (ARC-2) or with antisera against type I receptors. Sam- 
ples were subjected to SDS-gel electrophoresis, followed by anal- 
ysis using a Phosphorlmager. 
z25I-activin A and type II and type I receptors were immu- 
noprecipitated by antisera against ActR-II and ActR-IB, 
respectively  (Fig.  7  C).  However,  the  antisera  against 
ActR-I or the other known type I receptors did not immu- 
noprecipitate the type I  receptor complex. 125I-OP-1 also 
bound to  the  rat  pituitary cells,  but very weakly, and  a 
small amount of OP-l-type II receptor complex was im- 
munoprecipitated by the ActR-II antiserum. None of the 
type I receptor antisera immunoprecipitated the type I re- 
ceptor complex (Fig.  7  C). Taken together, FSH release 
from pituitary cells by activin A may be mediated, at least 
in part,  by ActR-II and ActR-IB, which does not trans- 
duce signals by OP-1. 
Mesoderm-lnducing Activity of OP-1 in 
Xenopus Embryos 
The mesoderm-inducing activity of OP-1 was examined by 
incubating Xenopus animal  caps  in  different  concentra- 
tions of OP-1 and comparing the effects of this factor with 
those of activin A. Mature OP-1 did not induce the meso- 
derm formation in Xenopus embryos. Therefore, we used 
the soluble OP-1, which is a  complex containing the ma- 
ture and pro-domains of OP-1, and much more soluble in 
physiological buffers than the mature OP-1 (Jones et al., 
1994). Whereas activin A induced strong elongation of an- 
imal caps, the earliest sign of mesoderm induction (Symes 
and Smith, 1987; Howard and Smith, 1993),  soluble OP-1 
caused caps only to become slightly misshapen (Fig. 8, 
A-E). Soluble OP-1 did not appear to inhibit the ability of 
activin  to  bring  about  elongation  (Fig.  8  F).  Similarly, 
while activin A  caused significant expression of the meso- 
derm-specific gene Brachyury at concentrations as low as 
20 pM, only weak expression of this gene was observed in 
response to 430 pM soluble OP-1 (Fig. 8 G), and even 4.3 
nM had little effect (not shown). Soluble OP-1 at 430 pM 
did not inhibit the ability of activin A  at 2,000  pM to in- 
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sected from Xenopus embryos and cultured in the absence of factors (A) or in the presence of 50 U/ml crude human activin A (,~400 pM 
activin) (B) or in the presence of 43 pM (C), 430 pM (D) or 4. 3 nM (E) soluble OP-1. Caps in (F) were cultured in the presence of 50 U/ 
ml activin A plus 430 pM soluble OP-1. Explants were photographed at the equivalent of stage 20. (G) Analysis of Brachyury (Xbra) ex- 
pression. Animal caps were cultured in the indicated concentrations (in ng/ml) of activin A or soluble OP-1, or in both factors, and fro- 
zen for analysis at the equivalent of stage 11. Soluble OP-1 at concentrations of 0.5, 5, and 50 ng/ml corresponds to 4.3, 43, and 430 pM, 
respectively, and 0.5, 5, and 50 ng/ml activin A is 20, 200, and 2,000 pM, respectively. 
duce expression of Brachyury.  These results indicate that 
OP-1 is a poor inducer of mesoderm. 
Discussion 
Type II serine/threonine kinase receptors bind ligands in 
the absence of type I receptors, whereas type I receptors 
require type II receptors for ligand binding (Wrana et al., 
1992; Inagaki et al.,  1993; Ebner et al., 1993b; Attisano et 
al., 1993; Franz6n et al., 1993). Moreover, a certain redun- 
dancy has been observed in the binding to type I receptors 
(Ebner et al., 1993a; Attisano et al., 1993; ten Dijke et al., 
1993c). Thus, the specificity of ligand binding is postulated 
to be more dependent on the type II receptors than on the 
type I  receptors. Before the present study, ActR-II and 
ActR-IIB had been shown to bind only activin and inhibin. 
Inhibin  is  a  weak competitor for activin binding.  Other 
ligands, e.g., TGF-f~s and BMP-4, do not bind to ActR-IIs 
(Mathews and Vale, 1991; Attisano et al., 1992; Mathews 
et al., 1992). Similarly, TI3R-II and DAF-4, a BMP type II 
receptor from C. elegans, had been shown to bind only the 
respective ligands (Lin et al., 1992; Estevez et al., 1993). In 
the present study we show that  OP-1, a  member of the 
BMP family, binds ActR-II in transfected COS-1 cells, al- 
though the binding affinity of OP-1 to ActR-II is two- to 
threefold lower than that of activin A.  Moreover, OP-1 
transduced  the  p3TP-Lux  transcription  signal  through 
ActR-II together with type I receptors. These results indi- 
cate that ActR-II can act as a functional type II receptor 
for OP-1, as well as for activin. 
OP-1  also bound to ActR-IIB1 and formed complexes 
with ActR-I, BMPR-IA  and  BMPR-IB.  However, OP-1 
induced p3TP-Lux transcriptional activation less efficiently 
through the complex of ActR-IIB1 and ActR-I, compared 
to those of ActR-II and ActR-I. In contrast, activin A was 
shown  to  efficiently  activate  p3TP-Lux  transcription 
through ActR-IIB  x and ActR-I (Attisano et al., 1993). 
In the presence of ActR-II, activin A  binds ActR-I and 
ActR-IB,  whereas  OP-1  binds  ActR-I,  BMPR-IA  and 
BMPR-IB, but not ActR-IB. These results suggest that the 
binding specificity of type I receptors is not solely deter- 
mined by type II receptors, but type I receptors appear to 
recognize complexes of ligands  and type II receptors. It 
was  recently suggested that  type I  receptors specify the 
signals  after  ligand  stimulation  (C~rcamo  et  al.,  1994). 
Thus, after the stimulation by activin A, ActR-I was found 
to mediate p3TP-Lux transcription, whereas ActR-IB trans- 
duced signals for p3TP-Lux transcription, growth inhibi- 
tion and PAI-1 production. Although we observed no dif- 
ferences between ActR-I and BMPR-IB in the functional 
assays investigated, they may possibly differ in the trans- 
duction of certain other signals. 
We  showed  that  both  activin  A  and  OP-1  inhibit 
[3H]thymidine incorporation in MvlLu cells with similar 
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was  neutralized by follistatin,  a  specific  inhibitor for  ac- 
tivins (Ueno  et al., 1987; Nakamura  et al., 1990). How- 
ever,  whereas  follistatin  inhibits  activin  A  at  equimolar 
amounts, a 10-fold excess was needed to inhibit OP-1. Fol- 
listatin is a monomeric glycoprotein, that is expressed  in 
parallel with activins  and is suggested  to modulate  their 
functions. These results suggest that OP-1  and activin A, 
having 43%  amino  acid sequence  identity (Ozkaynak  et 
al., 1990), share certain structural properties important for 
the interaction with receptors as well as with follistatin. 
Since OP-1 and activin have overlapping receptor bind- 
ing specificities,  it was interesting to compare the biologi- 
cal  effects  of  OP-1  with  those  of  activin. OP-1  induced 
erythroid differentiation in K562 cells, but the activity was 
lower than that of activin A. We showed that both OP-1 
and activin A  bind to ActR-II  and ActR-I in K562 cells, 
whereas  activin  A,  but  not  OP-1,  binds  to  ActR-IB  in 
these  cells. Recently,  K562  cells  were  found  to  express 
both ActR-II and ActR-IIB mRNAs (Hild6n et al., 1994). 
Since erythroid differentiation was more significant by ac- 
tivin A  than by OP-1, it is possible that ActR-IB or other 
receptors, which do not bind OP-1 efficiently, are impor- 
tant for erythroid differentiation in K562 cells. 
In contrast to activin A,  OP-1  did not show any FSH- 
releasing  activity. The rat pituitary cells  express  ActR-II 
and ActR-IB,  which were shown to bind activin A. OP-1 
bound to ActR-II very weakly in these cells; however, no 
type I receptor was observed after binding and cross-link- 
ing of 125I-OP-1, since OP-1 did not bind to ActR-IB in the 
presence of ActR-IIs. 
OP-1  has  been shown to be  a  multifunctional protein 
that has biological activities for BMPs  (t)zkaynak et al., 
1990;  Sampath  et  al.,  1992). We  have  shown  here  that 
OP-1 binds ActR-II and ActR-IIB, and transduces certain 
activin signals. Biological effects of OP-1, which are shared 
by activin A, included neutralization by follistatin and stim- 
ulation of erythroid differentiation. We  have also shown 
that OP-1 is a poor inducer of mesoderm in Xenopus em- 
bryos. It has recently been shown that mesoderm  induc- 
tion by Vgl, another member in the BMP subfamily, was 
blocked  by  truncated  ActR-IIs  (Schulte-Merker  et  al., 
1994). Thus, proteins in the BMP family have broader bio- 
logical functions than previously realized. Studies on the 
binding of the different members in BMP family to differ- 
ent type II and type I receptors will be important to under- 
stand the full range of their biological effects. It will also 
be important to determine whether ActR-II, together with 
type I receptors, transduces signals that are important for 
bone morphogenesis in vivo. 
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